Mylan Technologies Nov. 4 joined the growing list of companies challenging the validity on MonoSol Rx’s patent, which covers Indivior‘s Suboxone Film for treating opioid dependence (Mylan Technologies, Inc. v. MonoSol Rx LLC, P.T.A.B., IPR2017-00200, 11/4/16).
Mylan filed a petition for inter partes review (IPR) with the Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB), asserting that MonoSol Rx’s U.S. Patent No. 8,603,514 is invalid as obvious in light of prior publications and patents. The IPR was created by the America Invents Act to allow third-party challenges of existing patents.
MonoSol Rx licensed the ‘514 patent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.